Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016


Posted April 13, 2017 by Shirley

MarketResearchReportStore adds "Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016" latest studies, published in March 2017. It is a professional and in-depth study on the current state.

 
MarketResearchReportStore adds "Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016" latest studies, published in March 2017. It is a professional and in-depth study on the current state.

For a sample of this report, please email at: [email protected]

Description
Summary
‘Zydus Cadila Healthcare Ltd - Product Pipeline Review - 2016’, provides an overview of the Zydus Cadila Healthcare Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Zydus Cadila Healthcare Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Zydus Cadila Healthcare Ltd
- The report provides overview of Zydus Cadila Healthcare Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Zydus Cadila Healthcare Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Zydus Cadila Healthcare Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Request Sample Copy, please email at: [email protected]

Table Of Contents
Zydus Cadila Healthcare Ltd Snapshot 9
Zydus Cadila Healthcare Ltd Overview 9
Key Facts 9
Zydus Cadila Healthcare Ltd - Research and Development Overview 10
Key Therapeutic Areas 10
Zydus Cadila Healthcare Ltd - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Pipeline Products - Partnered Products 18
Partnered Products/Combination Treatment Modalities 19
Zydus Cadila Healthcare Ltd - Pipeline Products Glance 20
Zydus Cadila Healthcare Ltd - Late Stage Pipeline Products 20
Pre-Registration Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Zydus Cadila Healthcare Ltd - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Zydus Cadila Healthcare Ltd - Early Stage Pipeline Products 24
Preclinical Products/Combination Treatment Modalities 24
Discovery Products/Combination Treatment Modalities 25
Zydus Cadila Healthcare Ltd - Unknown Stage Pipeline Products 26
Unknown Products/Combination Treatment Modalities 26
Zydus Cadila Healthcare Ltd - Drug Profiles 27
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
(diphtheria + tetanus) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30

Browse Complete Report with TOC @
https://www.marketresearchreportstore.com/shop/zydus-cadila-healthcare-ltd-product-pipeline-review-2016

For report sample or more information, please feel free to contact us:
Shirley | Sales Director
Call: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/

About Us
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Market Research Report Store
Country United States
Categories Business , Marketing , Reports
Last Updated April 13, 2017